Health TrialsbyHealthPanel

Dexmedetomidine vs Lignocaine for Reducing Intubation-Induced Hemodynamic Responses in Cardiac Surgery: A Randomized Controlled Trial

ConditionsLaryngoscopic Stress ResponseDexmedetomidineLignocaine
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-65
SponsorRawalpindi Institute of Cardiology

About this trial

After confirming eligibility, written informed consent will be obtained by a trained team member who is not involved in assigning treatment or giving the study medication. Each participant will receive a unique study number to protect privacy. Participants will be randomly assigned to receive one of the study medications using a chance-based method.The study medication will be administered through a vein before placement of the breathing tube. Blood pressure and pulse rate will be measured before the procedure and at several time points after the breathing tube is inserted.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

None

Disqualifiers

Patients with known hypersensitivity to dexmedetomidine and Lignocaine.

Patients on medications that could interfere with the study (e.g., beta-blockers, calcium channel blockers).

Pregnant or lactating women.

Patients with a history of airway anomalies or difficult intubation.

Trial design

Design model

Parallel

Treatments tested in this trial

  • IV dexmedetomidine

    Drug

    0.5 Mcg/kg of Dexmedetomidine will be given 10 minutes before laryngoscopy

  • IV Lignocaine

    Drug

    Patients will be given 1.5 mg/kg of Lignocaine 3 minutes before laryngoscopy

Treatment groups

70 Participants
are divided into 2 treatment groups
Group A: Group DexmedActive comparator 1 intervention
Group B: Group LignocaineActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Mean Arterial Pressure

Time frame
It will be expressed in millimeters of mercury (mmHg) and measured using an arterial catheter immediately before intubation and then at 1,3,5 and 10 minutes after intubation.
2

Heart Rate

Time frame
It will be expressed as number of heart beats per minute and measured using pulse oximeter immediately before intubation and then at 1,3,5 and 10 minutes after intubation.

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Rawalpindi Institute of Cardiology

Lead sponsor

Source ClinicalTrials.gov
Apply now